Showing results (11-20 of 502) with videos related to
Sort By:
Pageof 51
International Journal of MS Care|January 17, 2022
Characterizing Long-term Disability Progression and Employment in NARCOMS Registry Participants with Multiple Sclerosis Taking Dimethyl FumarateAmber Salter, Samantha Lancia, Gary Cutter, et al.Multiple Sclerosis and Related Disorders|January 29, 2019
Validation of the SymptoMScreen with performance-based or clinician-assessed outcomesKathryn C Fitzgerald, Amber Salter, Tuula Tyry, et al.Therapeutic Advances in Neurological Disorders|July 15, 2021
A propensity-matched comparison of long-term disability worsening in patients with multiple sclerosis treated with dimethyl fumarate or fingolimodAmber Salter, Samantha Lancia, Gary Cutter, et al.Neurology. Clinical Practice|June 23, 2022
Sources of Cannabis Information and Medical Guidance for Neurologic Use: NARCOMS Survey of People Living With Multiple SclerosisAmber Salter, Gary Cutter, Ruth Ann Marrie, et al.International Journal of MS Care|January 17, 2022
A Survey of Cannabis Use in a Large US-Based Cohort of People with Multiple SclerosisAmber Salter, Robert J Fox, Gary Cutter, et al.Contemporary Clinical Trials|July 1, 2008
Bayesian interim analysis in clinical trialsXiao Zhang, Gary CutterHandbook of Clinical Neurology|February 11, 2014
Clinical trials in multiple sclerosisGary Cutter, Ludwig KapposAmerican Journal of Public Health|June 27, 2002
Mammography screening and differences in stage of disease by race/ethnicityJillian Jacobellis, Gary CutterAnnals of the New York Academy of Sciences|June 24, 2008
Rules of evidence for clinical trials: the science of finding the truth?Gary Cutter, Inmaculada AbanMultiple Sclerosis (Houndmills, Basingstoke, England)|August 12, 2025
Lost in dichotomization: Preserving statistical power and sensitivity in MS cognitive researchJeroen Van Schependom, Gary CutterPageof 51